Display options
Cite
Giri SN, Hyde DM, Haynam DR, et al. Attenuation of amiodarone induced lung fibrosis and phospholipidosis in hamsters, by treatment with the platelet activating factor receptor antagonist, WEB 2086. Mediators Inflamm. 1993;2(4):279-85doi: 10.1155/S0962935193000389.
Giri, S. N., Hyde, D. M., Haynam, D. R., & Casias, M. (1993). Attenuation of amiodarone induced lung fibrosis and phospholipidosis in hamsters, by treatment with the platelet activating factor receptor antagonist, WEB 2086. Mediators of inflammation, 2(4), 279-85. https://doi.org/10.1155/S0962935193000389
Giri, S N, et al. "Attenuation of amiodarone induced lung fibrosis and phospholipidosis in hamsters, by treatment with the platelet activating factor receptor antagonist, WEB 2086." Mediators of inflammation vol. 2,4 (1993): 279-85. doi: https://doi.org/10.1155/S0962935193000389
Giri SN, Hyde DM, Haynam DR, Casias M. Attenuation of amiodarone induced lung fibrosis and phospholipidosis in hamsters, by treatment with the platelet activating factor receptor antagonist, WEB 2086. Mediators Inflamm. 1993;2(4):279-85. doi: 10.1155/S0962935193000389. PMID: 18475534; PMCID: PMC2365411.
Copy Download .nbib Format: NLM
Share it on

Mediators Inflamm. 1993;2(4):279-85. doi: 10.1155/S0962935193000389.

Attenuation of amiodarone induced lung fibrosis and phospholipidosis in hamsters, by treatment with the platelet activating factor receptor antagonist, WEB 2086.

Mediators of inflammation

S N Giri, D M Hyde, D R Haynam, M Casias

Affiliations

  1. Departments of Veterinary Pharmacology and Toxicology University of California Davis CA 95616 USA.

PMID: 18475534 PMCID: PMC2365411 DOI: 10.1155/S0962935193000389

Abstract

Therapeutic use of amiodarone (AMD), a Class III antiarrhythmic drug is complicated by the development of lung fibrosis (LF) and phospholipidosis (PL). In the present study, the effectiveness of a PAF antagonist, WEB 2086, against AMD induced LF and PL has been tested in hamsters. The animals were randomly divided into four groups: (1) saline + H(2)O; (2) WEB + H(2)O; (3) saline + AMD; and (4) WEB + AMD. Saline or WEB (10 mg/kg i.p.) was given 2 days prior to intratracheal instillation of water or AMD (1.5 mumol/0.25 ml/100 g BW) and thereafter daily throughout the study. Twenty-eight days after intratracheal instillation, the animals were killed and the lungs processed for various assays. The amount of lung hydroxyproline, an index of LF, in saline + H(2)O, WEB + H(2)O, saline + AMD, and WEB + AMD groups were 959 +/- 46, 1035 +/- 51, 1605 +/- 85 and 1374 +/- 69 mug/lung, respectively. Total lung PL, an index of phospholipidosis, in the corresponding groups were 8.4 +/- 0.4, 8.3 +/- 0.3, 11.7 +/- 0.3 and 9.9 mug/lung. Lung malondialdehyde, an index of lipid peroxidation and superoxide dismutase activity in saline + H(2)O WEB + H(2)O, saline + AMD, and WEB + AMD were 93.0 +/- 4.3, 93.0 +/- 2.7, 138.9 +/- 6.0 and 109.0 +/- 3.8 nmol/lung and 359.7 +/- 13.9, 394.0 +/- 22.8, 497.5 +/- 19.7 and 425.5 +/- 4.9 units/lung, respectively. Administration of AMD alone caused significant increases in all the above indexes of lung toxicity, and treatment with WEB 2086 minimized the AMD induced toxicity as reflected by significant decreases in these indexes. Histopathological studies revealed a marked reduction in the extent and severity of lung lesions in the WEB + AMD group compared with the saline + AMD group. Treatment with WEB 2086 also reduced the acute mortality from 35% in saline + AMD group to 22% in WEB + AMD group. It was concluded that PAF is involved in the AMD induced lung fibrosis and phospholipidosis and that the PAF receptor antagonist may, therefore, be potentially useful in reducing AMD induced lung toxicity.

References

  1. Toxicol Appl Pharmacol. 1983 Oct;71(1):132-41 - PubMed
  2. J Cardiovasc Pharmacol. 1988 Jul;12(1):23-36 - PubMed
  3. Prostaglandins Leukot Essent Fatty Acids. 1989 May;36(2):85-92 - PubMed
  4. J Biol Chem. 1972 May 25;247(10):3170-5 - PubMed
  5. Exp Lung Res. 1987;13(4):401-16 - PubMed
  6. Chest. 1987 Feb;91(2):214-21 - PubMed
  7. Toxicol Appl Pharmacol. 1989 Sep 1;100(2):350-9 - PubMed
  8. Chest. 1986 Apr;89(4):617-8 - PubMed
  9. Exp Mol Pathol. 1983 Dec;39(3):317-26 - PubMed
  10. Exp Lung Res. 1984;6(1):1-10 - PubMed
  11. Exp Lung Res. 1991 May-Jun;17(3):569-87 - PubMed
  12. J Biol Chem. 1960 Mar;235:769-75 - PubMed
  13. Exp Mol Pathol. 1985 Apr;42(2):206-19 - PubMed
  14. J Pharmacol Exp Ther. 1988 Feb;244(2):774-9 - PubMed
  15. Arch Intern Med. 1979 Apr;139(4):425-8 - PubMed
  16. Can J Biochem Physiol. 1959 Aug;37(8):911-7 - PubMed
  17. Photochem Photobiol. 1987 Feb;45(2):191-7 - PubMed
  18. Jpn J Pharmacol. 1992 Oct;60(2):91-6 - PubMed
  19. Eur J Clin Invest. 1987 Feb;17(1):7-11 - PubMed
  20. Am Rev Respir Dis. 1987 Sep;136(3):770-2 - PubMed
  21. Circulation. 1982 Apr;65(4):819-24 - PubMed
  22. Am J Physiol. 1992 Nov;263(5 Pt 1):G587-92 - PubMed
  23. N Engl J Med. 1979 Jul 5;301(1):13-23 - PubMed
  24. Anal Biochem. 1979 Jun;95(2):351-8 - PubMed
  25. Chest. 1991 May;99(5):1177-82 - PubMed
  26. Ann Intern Med. 1982 Dec;97(6):839-45 - PubMed
  27. Exp Lung Res. 1985;9(1-2):119-33 - PubMed
  28. Mediators Inflamm. 1992;1(1):23-6 - PubMed
  29. J Pharmacol Exp Ther. 1992 Jul;262(1):127-32 - PubMed
  30. J Clin Invest. 1986 Dec;78(6):1701-6 - PubMed
  31. Am J Cardiol. 1976 Dec;38(7):934-44 - PubMed
  32. Clin Sci (Lond). 1992 Aug;83(2):127-38 - PubMed
  33. Cell Mol Biol. 1991;37(7):751-5 - PubMed
  34. Am Rev Respir Dis. 1988 Mar;137(3):510-8 - PubMed
  35. Am Heart J. 1983 Oct;106(4 Pt 2):788-97 - PubMed
  36. J Lab Clin Med. 1980 Dec;96(6):939-42 - PubMed
  37. Arch Biochem Biophys. 1961 May;93:440-7 - PubMed
  38. J Clin Invest. 1988 Dec;82(6):2045-55 - PubMed
  39. J Lab Clin Med. 1980 Dec;96(6):954-64 - PubMed
  40. Biochem Biophys Res Commun. 1991 Jun 14;177(2):704-10 - PubMed
  41. Prostaglandins Leukot Essent Fatty Acids. 1990 Oct;41(2):71-82 - PubMed
  42. J Clin Invest. 1982 Nov;70(5):1058-65 - PubMed
  43. Am Heart J. 1983 Oct;106(4 Pt 2):887-94 - PubMed
  44. Can J Cardiol. 1989 Mar;5(2):98-104 - PubMed
  45. Am Rev Respir Dis. 1983 Jul;128(1):71-6 - PubMed

Publication Types